Bosutinib
- Generic Name
- Bosutinib
- Brand Names
- Bosulif
- Drug Type
- Small Molecule
- Chemical Formula
- C26H29Cl2N5O3
- CAS Number
- 380843-75-4
- Unique Ingredient Identifier
- 5018V4AEZ0
- Background
Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR-ABL fusion prote...
- Indication
用于治疗对既往治疗无效的慢性、加速期或急变期Ph+的慢性粒细胞白血病（CML）患者。
- Associated Conditions
- Accelerated Phase Chronic Myelogenous Leukemia (CML), Chronic Phase Chronic Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
Bosutinib in Elderly Chronic Myeloid Leukemia
- First Posted Date
- 2016-06-23
- Last Posted Date
- 2023-02-03
- Target Recruit Count
- 65
- Registration Number
- NCT02810990
- Locations
- 🇮🇹
Policlinico di Careggi, Firenze, Italy
🇮🇹S.O.C. di Ematologia - Azienda Ospedaliera - SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
🇮🇹Azienda Ospedaliero - Universitaria Ospedali Riuniti Umberto I - G.M. LANCISI - G. SALESI, Ancona, Italy
Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2016-05-25
- Last Posted Date
- 2020-11-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT02782403
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Failing TKIs Therapy
- Conditions
- Interventions
- First Posted Date
- 2015-12-23
- Last Posted Date
- 2020-11-05
- Lead Sponsor
- University of Milano Bicocca
- Target Recruit Count
- 2
- Registration Number
- NCT02638467
- Locations
- 🇮🇹
Ospedale San Raffaele, Milano, MI, Italy
🇮🇹ASST-Monza, Monza, Italy/MB, Italy
A Study To Describe The Real World Use Of Bosutinib In The UK And Netherlands
- First Posted Date
- 2015-09-10
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 87
- Registration Number
- NCT02546375
- Locations
- 🇬🇧
Hammersmith Hospital, London, United Kingdom
🇬🇧Nottingham University Hospital, Nottingham, United Kingdom
🇬🇧Royal Liverpool Hospital, Liverpool, Merseyside, United Kingdom
Safety And Efficacy Of Bosutinib
- First Posted Date
- 2015-07-17
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 702
- Registration Number
- NCT02501330
CML Treated With Bosutinib After Relapse
- First Posted Date
- 2015-05-15
- Last Posted Date
- 2020-04-29
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 30
- Registration Number
- NCT02445742
- Locations
- 🇪🇸
C. H. U. de Gran Canaria Dr. Negrín, Gran Canaria, Spain
🇪🇸H. U. Son Espases, Palma de Mallorca, Spain
🇪🇸Clínica Quirón Zaragoza S.A., Zaragoza, Spain
Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML
- Conditions
- B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveBlasts More Than 5 Percent of Bone Marrow Nucleated CellsCD22 PositivePhiladelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous LeukemiaRecurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveRefractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Interventions
- First Posted Date
- 2014-12-09
- Last Posted Date
- 2023-07-17
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT02311998
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors
- First Posted Date
- 2014-08-29
- Last Posted Date
- 2021-12-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 163
- Registration Number
- NCT02228382
- Locations
- 🇺🇸
University of Miami Hospital & Clinics, Miami, Florida, United States
🇺🇸Siteman Cancer Center - West County, Creve Coeur, Missouri, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
- Conditions
- Interventions
- First Posted Date
- 2014-05-05
- Last Posted Date
- 2021-05-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 536
- Registration Number
- NCT02130557
- Locations
- 🇺🇸
Pacific Cancer Medical Center, Inc., Anaheim, California, United States
🇺🇸The Emory Clinic, Atlanta, Georgia, United States
🇺🇸Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
Drug Interaction Study Between Bosutinib And Dabigatran
- First Posted Date
- 2014-04-03
- Last Posted Date
- 2014-06-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 27
- Registration Number
- NCT02102633
- Locations
- 🇺🇸
Pfizer Investigational Site, DeLand, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.